The use of nanotechnology in medicine holds the potential to essentially improve diagnosis, treatment and monitoring of disease activity. To foster research in this area, the European Commission is funding the collaborat...
A recent medical study published in the Journal of Opioid Management found that breakthrough pain (BTP) is more common in patients without cancer than those with cancer. And the noncancer patients were more lifestyle impaired than those with cancer.
miRagen Therapeutics, Inc., a biopharmaceutical company focused on improving patients’ lives by developing innovative microRNA (miRNA)-based therapeutics for cardiovascular and muscle disease, and the University of Colorado (CU) announced today that they have entered into sponsored research and licensing agreements to collaborate on miRNA therapeutics discovery and development.
By combining an iron oxide nanoparticle, a tumor-targeting peptide, and a therapeutic nucleic acid into one construct, a team of investigators from the Massachusetts General Hospital and Harvard Medical School have creat...
Gold nanoparticles are showing real promise as vehicles for efficiently delivering therapeutic nucleic acids, such as disease-fighting genes and small interfering RNA (siRNA) molecules, to tumors. Now, a team of investig...
In recent years, studies have shown that for many types of cancer, combination drug therapy is more effective than single drugs. However, it is usually difficult to get the right amount of each drug to the tumor. Now, re...
Though targeted nanoparticle-based imaging agents and therapeutics for diagnosing and treating cancer are making their way to and through the clinical trials process, researchers still do not have a good understanding of...
Lumiphore Inc., a portfolio company of Nanostart AG, has signed a global cooperation with Algeta ASA (Oslo Stock Exchange, ticker: ALGETA), a leading company specializing in innovative radiopharmaceutical therapies to tr...
Tekmira Pharmaceuticals Corporation, a leader in RNA interference (RNAi) therapeutics, announced today that, together with collaborators at the National Cancer Institute (NCI), it has published promising preclinical data in the prominent journal Cancer Research (Lee et al, Definition of Ubiquitination Modulator COP1 as a Novel Therapeutic Target in Human Hepatocellular Carcinoma.
NanoBio Corporation today announced that company founder and chief executive officer James R. Baker, Jr. MD, will meet with renown scientists at the 6th Annual Grand Challenges in Global Health (GCGH) Meeting, taking place from Oct. 25-27 in Seattle, Wash., to present data illustrating the potential of the company’s nanoemulsion-based needle-free intranasal vaccine platform to alleviate the suffering caused by infectious diseases in developing countries.
Terms
While we only use edited and approved content for Azthena
answers, it may on occasions provide incorrect responses.
Please confirm any data provided with the related suppliers or
authors. We do not provide medical advice, if you search for
medical information you must always consult a medical
professional before acting on any information provided.
Your questions, but not your email details will be shared with
OpenAI and retained for 30 days in accordance with their
privacy principles.
Please do not ask questions that use sensitive or confidential
information.
Read the full Terms & Conditions.